NUCALA® Special Drug Use Investigation (EGPA, Long-term)

Status Active, not recruiting

Clinical Trial Summary

This study is a drug use investigation program of NUCALA. The objective of this study is to collect and assess information on the safety and effectiveness of the long-term use of NUCALA SC injection in daily clinical practice in subjects with Eosinophilic Granulomatosis with Polyangiitis (EGPA). All subjects who administered NUCALA for the treatment of EGPA after its approval of indication will be included in the study. In addition, after the approval, subjects who had already received NUCALA for EGPA prior to the conclusion of the contract will also be included. Approximately 300 subjects will be included in the study. The observation period per subject is up to 96 weeks (2 years) from the start of NUCALA administration for EGPA at a maximum. If a subject has withdrawn from/terminated administration of NUCALA, it will be until the withdrawal/termination. Additionally, to consider the safety and effectiveness of NUCALA administration in subjects who had withdrawn from/terminated due to symptom improvement, 48 weeks (1 year) follow-up investigation should be conducted as much as possible. The total study duration will be approximately 3 years (2 years observation period and 1 year follow-up) from the approval of EGPA indication to the lifting of approval condition. NUCALA is a registered trademark of the GlaxoSmithKline [GSK] group of companies.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Churg-Strauss Syndrome

Clinical Trial Details

NCT number	NCT03557060
Study type	Observational
Source	GlaxoSmithKline
Contact
Status	Active, not recruiting
Phase
Start date	June 25, 2018
Completion date	May 31, 2024

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT01729624` - PRO Development for ANCA Associated Vasculitis	N/A
Completed	`NCT02190916` - Vasculitis Illness Perception (VIP) Study	N/A
Recruiting	`NCT02967068` - VCRC Tissue Repository
Completed	`NCT02190942` - VCRC Patient Contact Registry Patient-Reported Data Validation Study
Completed	`NCT00307593` - RATTRAP: Infliximab Versus Rituximab in Systemic Necrotizing Vasculitides	N/A
Completed	`NCT02190929` - Educational Needs of Patients With Systemic Vasculitis	N/A
Active, not recruiting	`NCT00006055` - Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases	N/A
Terminated	`NCT00424749` - Rituxan in Churg Strauss Syndrome With Renal Involvement	Phase 2
Completed	`NCT00307671` - Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years	Phase 4
Active, not recruiting	`NCT00399399` - CHUSPAN SCS BP Treatment of Churg–Strauss Syndrome Without Poor-Prognosis Factors	Phase 4
Completed	`NCT02020889` - A Study to Investigate Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis	Phase 3
Completed	`NCT02176070` - Reproductive Health in Men and Women With Vasculitis	N/A
Completed	`NCT00266565` - Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic Syndrome	Phase 1/Phase 2
Recruiting	`NCT06046222` - Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis	Phase 2
Recruiting	`NCT04316494` - Hydroxychloroquine in ANCA Vasculitis Evaluation	Phase 4
Active, not recruiting	`NCT04551989` - Mepolizumab Long-term Study to Assess Real World Safety and Effectiveness of Eosinophilic Granulomatosis With Polyangiitis (EGPA) in Japan
Recruiting	`NCT04671446` - Identification of Autoantigens in EGPA and Severe Eosinophilic Asthma
Completed	`NCT03036670` - Eosinophilic Granulomatosis With Polyangiitis Cohort
Terminated	`NCT02728271` - Immuno-ablation With Chemoimmunoradiation and Autologous Stem Cell Transplant for Churg-Strauss Syndrome	Early Phase 1
Recruiting	`NCT00315380` - Longitudinal Study for Eosinophilic Granulomatosis With Polyangiitis